Browsing Radiotherapy and Imaging by author "Eeles, Rosalind"
Now showing items 101-120 of 148
-
Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium.
Khankari, NK; Murff, HJ; Zeng, C; Wen, W; Eeles, RA; et al. (SPRINGERNATURE, 2016-08-23)BACKGROUND: Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been ... -
Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies.
Larson, NB; McDonnell, S; Albright, LC; Teerlink, C; Stanford, J; et al. (WILEY, 2016-09-01)Rare variants (RVs) have been shown to be significant contributors to complex disease risk. By definition, these variants have very low minor allele frequencies and traditional single-marker methods for statistical analysis ... -
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
Gonzalez, D; Mateo, J; Stenzinger, A; Rojo, F; Shiller, M; et al. (WILEY, 2021-02-25)Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) ... -
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Lecarpentier, J; Silvestri, V; Kuchenbaecker, KB; Barrowdale, D; Dennis, J; et al. (AMER SOC CLINICAL ONCOLOGY, 2017-07-10)Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge- ... -
Prostate Cancer Germline Variations and Implications for Screening and Treatment.
Dias, A; Kote-Jarai, Z; Mikropoulos, C; Eeles, R (COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2018-09-04)Prostate cancer (PCa) is a highly heritable disease, and rapid evolution of sequencing technologies has enabled marked progression of our understanding of its genetic inheritance. A complex polygenic model that involves ... -
Prostate Cancer Risk by BRCA2 Genomic Regions.
Nyberg, T; Frost, D; Barrowdale, D; Evans, DG; Bancroft, E; et al. (ELSEVIER, 2020-10-01)A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 3') wherein pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk than PVs elsewhere in the BRCA2 gene. Using a ... -
Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
McHugh, J; Saunders, EJ; Dadaev, T; McGrowder, E; Bancroft, E; et al. (SPRINGERNATURE, 2022-06-01)Prostate cancer is the second most common solid tumour in men worldwide and it is also the most common cancer affecting men of African descent. Prostate cancer incidence and mortality vary across regions and populations. ... -
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Luedeke, M; Rinckleb, AE; FitzGerald, LM; Geybels, MS; Schleutker, J; et al. (OXFORD UNIV PRESS, 2016-12-15)Molecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk ... -
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.
Huynh-Le, M-P; Karunamuni, R; Fan, CC; Asona, L; Thompson, WK; et al. (SPRINGERNATURE, 2022-02-12)BACKGROUND: Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased ... -
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Nyberg, T; Frost, D; Barrowdale, D; Evans, DG; Bancroft, E; et al. (ELSEVIER, 2020-01-01)BACKGROUND: BRCA1 and BRCA2 mutations have been associated with prostate cancer (PCa) risk but a wide range of risk estimates have been reported that are based on retrospective studies. OBJECTIVE: To estimate relative and ... -
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; et al. (NATURE PUBLISHING GROUP, 2018-03-20)This corrects the article DOI: 10.1038/bjc.2017.429. -
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY).
Bancroft, EK; Saya, S; Brown, E; Thomas, S; Taylor, N; et al. (BMJ PUBLISHING GROUP, 2020-04-01)BACKGROUND: Germline TP53 gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening is recommended for female TP53 pv ... -
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Bancroft, EK; Saya, S; Page, EC; Myhill, K; Thomas, S; et al. (WILEY, 2019-02-01)OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic ... -
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?
McBride, KA; Ballinger, ML; Schlub, TE; Young, M-A; Tattersall, MHN; et al. (SPRINGER, 2017-07-01)Germline TP53 mutation carriers are at high risk of developing a range of cancers. Effective cancer risk management is an important issue for these individuals. We assessed the psychosocial impact in TP53 mutation carriers ... -
Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.
Bonilla, C; Lewis, SJ; Martin, RM; Donovan, JL; Hamdy, FC; et al. (BMC, 2016-04-04)BACKGROUND: Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates ... -
Quantifying the Genetic Correlation between Multiple Cancer Types.
Lindström, S; Finucane, H; Bulik-Sullivan, B; Schumacher, FR; Amos, CI; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Background: Many cancers share specific genetic risk factors, including both rare high-penetrance mutations and common SNPs identified through genome-wide association studies (GWAS). However, little is known about the ... -
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; et al. (OXFORD UNIV PRESS INC, 2020-02-01)BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk ... -
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson, Q; Brook, MN; Dadaev, T; Wakerell, S; Saunders, EJ; et al. (ELSEVIER, 2021-01-09)BACKGROUND: Germline ATM mutations are suggested to contribute to predisposition to prostate cancer (PrCa). Previous studies have had inadequate power to estimate variant effect sizes. OBJECTIVE: To precisely estimate the ... -
Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
Mijuskovic, M; Saunders, EJ; Leongamornlert, DA; Wakerell, S; Whitmore, I; et al. (SPRINGERNATURE, 2018-07-03)BACKGROUND: Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal. We sought to identify a signature of rare inherited variants that distinguishes between these ... -
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell, A; Ashcroft, L; Fallowfield, L; Eccles, DM; Eeles, RA; et al. (AMER ASSOC CANCER RESEARCH, 2018-01-01)Background: Ovarian suppression in premenopausal women is known to reduce breast cancer risk. This study aimed to assess uptake and compliance with ovarian suppression using the luteinizing hormone releasing hormone (LHRH) ...